Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Isabelle H. Winer"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommen
Externí odkaz:
https://doaj.org/article/2a2de03e79f148b6ad3b812d310abfe8
Autor:
Hagit Kopel, Alina Bogdanov, Jessamine P. Winer-Jones, Christopher Adams, Isabelle H. Winer, Machaon Bonafede, Van Hung Nguyen, James A. Mansi
Publikováno v:
Diseases, Vol 12, Iss 1, p 16 (2024)
Influenza and COVID-19 contribute significantly to the infectious disease burden during the respiratory season, but their relative burden remains unknown. This study characterizes the frequency and severity of medically attended COVID-19 and influenz
Externí odkaz:
https://doaj.org/article/535737d3c85f40fc9df9b053f4e5b97b
Autor:
Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV d
Externí odkaz:
https://doaj.org/article/6b66e6d3a8c14c57a799f9529b689f38
Autor:
Kopel, Hagit, Bogdanov, Alina, Winer-Jones, Jessamine P., Adams, Christopher, Winer, Isabelle H., Bonafede, Machaon, Nguyen, Van Hung, Mansi, James A.
Publikováno v:
Diseases; Jan2024, Vol. 12 Issue 1, p16, 13p
Autor:
Kong, Amanda M., Winer, Isabelle H., Zimmerman, Nicole M., Diakun, David, Bloomfield, Adam, Gonzales, Tara, Fergie, Jaime, Goldstein, Mitchell, Krilov, Leonard R.
Publikováno v:
American Journal of Perinatology; Oct2023, Vol. 40 Issue 14, p1529-1536, 8p